vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v16i4.1779vsp-1791Research ArticleКЛИНИЧЕСКОЕ НАБЛЮДЕНИЕCLINICAL OBSERVATIONSОПЫТ УСПЕШНОГО ПРИМЕНЕНИЯ ЭТАНЕРЦЕПТА У ПАЦИЕНТКИ С ПОЛИАРТИКУЛЯРНЫМ ВАРИАНТОМ ЮВЕНИЛЬНОГО ИДИОПАТИЧЕСКОГО АРТРИТА С ОБЗОРОМ ПРЕДИКТОРОВ ХОРОШЕГО ОТВЕТА НА ПРОВОДИМУЮ ТЕРАПИЮSUCCESSFUL USE OF ETANERCEPT IN A PATIENT WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WITH AN OVERVIEW OF THE PREDICTORS OF A GOOD RESPONSE TO ONGOING THERAPYКарасёваА. В.KarasevaAnna V.

Москва

Moscow

https://orcid.org/0000-0002-3874-4721АлексееваЕ. И.AlexeevaEkaterina I.

Алексеева Екатерина Иосифовна - доктор медицинских наук, профессор, чл.-корр. РАН, заведующая ревматологическим отделением НМИЦ здоровья детей, декан педиатрического факультета Первого МГМУ им. И.М. Сеченова.

119991, Москва, Ломоносовский пр-т, д. 2, стр. 1, тел.: +7 (499) 134-02-97

Moscow

alekatya@yandex.ruДворяковскаяТ. М.DvoryakovskayaTatyana M.

Москва

Национальный медицинский исследовательский центр здоровья детейРоссияNational Medical Research Center of Children’s HealthRussian FederationНациональный медицинский исследовательский центр здоровья детей; Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияNational Medical Research Center of Children’s Health; Sechenov First Moscow State Medical UniversityRussian Federation201727092017164321325Copyright © Карасёва А.В., Алексеева Е.И., Дворяковская Т.М., 20172017Карасёва А.В., Алексеева Е.И., Дворяковская Т.М.Karaseva A.V., Alexeeva E.I., Dvoryakovskaya T.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1791

Представлен  случай полиартикулярного варианта ювенильного  идиопатического артрита, резистентного  к терапии метотрексатом и нестероидными противовоспалительными препаратами. Ребенку был назначен ингибитор фактора некроза опухоли    этанерцепт в дозе 0,4 мг/кг массы тела 2 раза/нед. Лечение этанерцептом индуцировало ремиссию заболевания,  обеспечило  восстановление  функции в суставах. Предикторами хорошего ответа на этанерцепт являлись младший возраст, непродолжительное течение заболевания, применение малого числа иммунодепрессантов до назначения этанерцепта, отсутствие сопутствующего применения глюкокортикостероидов, отсутствие увеита. 

The  article  presents  a case  of  polyarticular  juvenile  idiopathic  arthritis  resistant  to  methotrexate  therapy  and  nonsteroidal  antiinflammatory drugs.  The child was prescribed  a tumor necrosis  factor   inhibitor etanercept  at a dose  of 0.4 mg/kg body weight2 times/week. The treatment  with etanercept  induced remission of the disease, ensured the function restoration  in the joints. The predictors  of a good response  to etanercept  were the younger  age, the short  course  of the disease,  the use of a small number of immunosuppressants  before prescription of etanercept, the absence of concomitant use of glucocorticosteroids,  and the absence of uveitis.

детиювенильный идиопатический артриттерапияэтанерцепт предикторы ответаchildrenjuvenile idiopathic arthritistherapyetanerceptresponse predictorsКомпания «Пфайзер»Supported by PfizerReferencesWallace CA, Giannini EH, Huang B, et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63(7):929–936. doi: 10.1002/acr.20497.Wallace CA, Giannini EH, Huang B, et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63(7):929–936. doi: 10.1002/acr.20497.Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol. 1998;25(10):1991–1994.Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol. 1998;25(10):1991–1994.Brewer EJ Jr, Bass J, Baum J, et al. Current proposed revision of JRA Criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Section of The Arthritis Foundation. Arthritis Rheum. 1977; 20(2 Suppl):195–199.Brewer EJ Jr, Bass J, Baum J, et al. Current proposed revision of JRA Criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Section of The Arthritis Foundation. Arthritis Rheum. 1977; 20(2 Suppl):195–199.Woo P, Wedderburn LR. Juvenile chronic arthritis. Lancet. 1998; 351(9107):969–973. doi: 10.1016/s0140-6736(05)60640-x.Woo P, Wedderburn LR. Juvenile chronic arthritis. Lancet. 1998; 351(9107):969–973. doi: 10.1016/s0140-6736(05)60640-x.Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48(4):1093–1101. doi: 10.1002/art.10885.Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48(4):1093–1101. doi: 10.1002/art.10885.Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 2013;65(10):2499–2512. doi: 10.1002/art.38092.Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 2013;65(10):2499–2512. doi: 10.1002/art.38092.Kearsley-Fleet L, Davies R, Lunt M, et al. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford). 2016;55(5): 840–847. doi: 10.1093/rheumatology/kev434.Kearsley-Fleet L, Davies R, Lunt M, et al. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford). 2016;55(5): 840–847. doi: 10.1093/rheumatology/kev434.Otten MH, Prince FH, Armbrust W, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA. 2011;306(21):2340-2347. doi: 10.1001/jama.2011.1671.Otten MH, Prince FH, Armbrust W, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA. 2011;306(21):2340-2347. doi: 10.1001/jama.2011.1671.Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63(4):465–482. doi: 10.1002/acr.20460.Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63(4):465–482. doi: 10.1002/acr.20460.van Dijkhuizen EH, Wulffraat NM. Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review. Ann Rheum Dis. 2015;74(11):1996-2005. doi: 10.1136/annrheumdis-2014-205265.van Dijkhuizen EH, Wulffraat NM. Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review. Ann Rheum Dis. 2015;74(11):1996-2005. doi: 10.1136/annrheumdis-2014-205265.Федеральные клинические рекомендации по ведению пациентов с юношеским артритом. — М.: Союз педиатров России; 2017. [Federal’nye klinicheskie rekomendatsii po vedeniyu patsientov s yunosheskim artritom. Moscow: Soyuz pediatrov Rossii; 2017. (In Russ).] Доступно по: http://www.pediatr-russia.ru/sites/default/files/file/kr_yua.pdf. Ссылка активна на 18.07.2017.Федеральные клинические рекомендации по ведению пациентов с юношеским артритом. — М.: Союз педиатров России; 2017. [Federal’nye klinicheskie rekomendatsii po vedeniyu patsientov s yunosheskim artritom. Moscow: Soyuz pediatrov Rossii; 2017. (In Russ).] Доступно по: http://www.pediatr-russia.ru/sites/default/files/file/kr_yua.pdf. Ссылка активна на 18.07.2017.Solari N, Palmisani E, Consolaro A, et al. Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2013;40(2): 192–200. doi: 10.3899/jrheum.120842.Solari N, Palmisani E, Consolaro A, et al. Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2013;40(2): 192–200. doi: 10.3899/jrheum.120842.Geikowski T, Becker I, Horneff G; German BIKER Registry Collaborative Study Group. Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis. Rheumatology (Oxford). 2014;53(7):1245-1249. doi: 10.1093/rheumatology/ket490.Geikowski T, Becker I, Horneff G; German BIKER Registry Collaborative Study Group. Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis. Rheumatology (Oxford). 2014;53(7):1245-1249. doi: 10.1093/rheumatology/ket490.Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68(5):635–641. doi: 10.1136/ard.2007.087411.Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68(5):635–641. doi: 10.1136/ard.2007.087411.Southwood TR, Foster HE, Davidson JE, et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford). 2011;50(1):189–195. doi: 10.1093/rheumatology/keq308.Southwood TR, Foster HE, Davidson JE, et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford). 2011;50(1):189–195. doi: 10.1093/rheumatology/keq308.Papsdorf V, Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford). 2011;50(1):214–221. doi: 10.1093/rheumatology/keq292.Papsdorf V, Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford). 2011;50(1):214–221. doi: 10.1093/rheumatology/keq292.Alexeeva EI, Namazova-Baranova LS, Bzarova TM, et al. Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children’s Health, Russia. Pediatr Rheumatol Online J. 2017;15(1):51. doi: 10.1186/s12969-017-0178-9.Alexeeva EI, Namazova-Baranova LS, Bzarova TM, et al. Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children’s Health, Russia. Pediatr Rheumatol Online J. 2017;15(1):51. doi: 10.1186/s12969-017-0178-9.Consolaro A, Bracciolini G, Ruperto N, et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum. 2012;64(7):2366-2374. doi: 10.1002/art.34373.Consolaro A, Bracciolini G, Ruperto N, et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum. 2012;64(7):2366-2374. doi: 10.1002/art.34373.Anink J, Van Suijlekom-Smit LW, Otten MH, et al. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Arthritis Res Ther. 2015;17:200. doi: 10.1186/s13075-015-0723-1.Anink J, Van Suijlekom-Smit LW, Otten MH, et al. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Arthritis Res Ther. 2015;17:200. doi: 10.1186/s13075-015-0723-1.

The authors declare that there are no conflicts of interest present.